Evidence map›Paper›PMID 40795048›Full record

ArticleRheumatology (Oxford, England)2025

Prevalence and functional characterization of anti-interferon autoantibodies in inflammatory myopathies.

Iago Pinal-Fernandez, Lindsey B Rosen, Jose Luis Gomez-Vazquez, Maria Casal-Dominguez, Serena Lee, Jose C Milisenda, Katherine Pak, Xavier Solanich, Steven M Holland, Albert Selva-O'Callaghan and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Rheumatology (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Iago Pinal-FernandezMuscle Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.
Lindsey B RosenLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Jose Luis Gomez-VazquezDepartment of Internal Medicine, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.
Maria Casal-DominguezMuscle Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.
Serena LeeLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Jose C MilisendaBarcelona University, Barcelona, Spain.
Katherine PakMuscle Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.
Xavier SolanichDepartment of Internal Medicine, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.
Steven M HollandLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Albert Selva-O'CallaghanSystemic Autoimmune Disease Section, Vall d'Hebron Institute of Research, Barcelona, Spain.
Andrew L MammenMuscle Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.

Funding

Carlos III National Health Institute PI23/00651Intramural NIH HHS Z99 AR999999National Institute of Allergy and Infectious DiseasesNatural History ProtocolNHLBI NIH HHSNIAMS NIH HHSNIHNIH HHS
6 · The paper itself

Abstract

objectivesFunctional autoantibodies targeting IFNs can lead to immunodeficiency and have been implicated in various autoimmune diseases. Despite the critical role of interferons in myositis pathogenesis, the significance of anti-IFN autoantibodies in inflammatory myopathies remains poorly understood. This study aimed to investigate the prevalence and functional impact of anti-IFN autoantibodies in patients with myositis.

methodsSerum samples from 147 patients across two independent myositis cohorts were screened for autoantibodies against IFN-α, IFN-β, IFN-ω and IFN-γ. An independent validation cohort of 34 patients was also assessed for autoantibodies against type I IFN. Functional assays were performed to evaluate whether these autoantibodies inhibited type I IFN-induced signal transduction or protein expression.

resultsIncreased binding to IFN-α, IFN-β, IFN-ω and IFN-γ was detected in 3.9%, 5.5%, 2.8% and 0.7% of patients, respectively. Their prevalence did not significantly differ among myositis subtypes. Functional assays revealed no relevant inhibitory effects on type I IFN signalling.

conclusionsA subset of patients with inflammatory myopathies harbour low-level anti-IFN autoantibodies, but the absence of functional activity suggests that these autoantibodies are unlikely to directly contribute to disease pathogenesis.

Indexed as

AutoantibodiesInterferonsMyositisAdultAgedFemaleHumansInterferon-gammaInterferon Type IMaleMiddle AgedPrevalenceSignal TransductionAutoantibodiesInterferon-gammaInterferonsInterferon Type Ianti-interferon autoantibodiesantisynthetase syndromeautoantibodiesdermatomyositisimmune-mediated necrotizing myositisinclusion body myositisinterferonmyositis

Identifiers

PMID40795048
PMCPMC12671877

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.